Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>Major averages in the US (S&amp;P 500, Dow, Russell 2000) and Europe (STOXX 600 &amp; 50) each had throwbacks to their prior breakout levels last week, with all making successful tests of support amid reports of a potential setback in trade negotiations. We continue to believe dips should be bought as the weight of the evidence continues to point to a new leg higher for the broad equity market. In today’s report we highlight attractive Groups and stocks within Consumer Discretionary, Health Care, and Technology: Retailers, Jewelry, Pharmaceuticals, Mega-Cap, Pharmaceuticals, Small-Cap, and Wireless Components.</p>

Major averages in the US (S&amp;P 500, Dow, Russell 2000) and Europe (STOXX 600 &amp; 50) each had throwbacks to their prior breakout levels last week, with all making successful tests of support amid reports of a potential setback in trade negotiations. We continue to believe dips should be bought as the weight of the evidence continues to point to a new leg higher for the broad equity market. In today’s report we highlight attractive Groups and stocks within Consumer Discretionary, Health Care, and Technology: Retailers, Jewelry, Pharmaceuticals, Mega-Cap, Pharmaceuticals, Small-Cap, and Wireless Components.

U. S. Equity Strategy: Small-Caps Closing the Gap

United States

Heron Therapeutics, Inc. operates as a biotechnology company. The Company offers proprietary biochronomer drug delivery technology which is designed to improve the therapeutic profile of injectable pharmaceuticals, as well as focuses on identifying current therapies with the potential to be reformulated.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Heron Therapeutics (HRTX US)

U. S. Equity Strategy: Small-Caps Closing the Gap

Major averages in the US (S&P 500, Dow, Russell 2000) and Europe (STOXX 600 & 50) each had throwbacks to their prior breakout levels last...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)